H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C. Wainwright analyst Joseph Pantginis maintained a buy rating and $42 price target on Edgewise Therapeutics, Inc. (NASDAQ:EWTX) on October 13, supporting the optimistic rating with the company’s promising developments in the treatment of Becker muscular dystrophy (BMD).

Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

The analyst stated that Edgewise Therapeutics, Inc.’s (NASDAQ:EWTX) investigational drug, sevasemten, is highlighted as a potential first-in-class therapy to prevent muscle damage in BMD patients. The condition does not have any currently approved treatments, and the drug’s progress, which was highlighted at the 2025 International Annual Congress of the World Muscle Society, reflects its potential to address the unmet needs for BMD.

Therefore, sevasemten’s promising clinical results, especially in improving functional outcomes, support the analyst’s bullish outlook for Edgewise Therapeutics, Inc. (NASDAQ:EWTX).

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company that develops, discovers, and commercializes innovative treatments for serious, rare muscle disorders with considerable unmet medical needs and severe cardiac conditions. Its lead product candidate is sevasemten (EDG-5506), an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies.

While we acknowledge the potential of EWTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EWTX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.